Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Barr/Enhance Acquisition’s First Product Expected To Be Oxybutynin Ring

  • News

Executive Summary

Barr's first product to market from its acquisition of Enhance Pharmaceuticals is expected to be a vaginal ring for the treatment of urinary incontinence

You may also be interested in...



Barr buys incontinence product rights

Barr acquires worldwide rights to Phase II oxybutynin transvaginal ring under an agreement with Schering AG. Barr has been developing the incontinence agent for Schering AG since its acquisition of Enhance Pharmaceuticals in 2002 (1"The Pink Sheet" April 1, 2002, p. 30)...

Barr buys incontinence product rights

Barr acquires worldwide rights to Phase II oxybutynin transvaginal ring under an agreement with Schering AG. Barr has been developing the incontinence agent for Schering AG since its acquisition of Enhance Pharmaceuticals in 2002 (1"The Pink Sheet" April 1, 2002, p. 30)...

Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products

Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation

Table

View full table

Tags:
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS039570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By